SLS and TERN are advancing leukemia therapies, with TERN-701 targeting CML and GPS positioned as a Phase 3 maintenance ...

Merck is buying oncology company Terns Pharmaceuticals in a deal valued at approximately $6.7 billion as the pharmaceutical ...

By Siddhi Mahatole March 25 (Reuters) - Merck said on Wednesday it would buy biotech firm Terns Pharma for $6.7 billion, as ...

Merck is bulking up its portfolio ahead of its best-selling cancer drug Keytruda losing patent protection in 2028.

Merck’s MRK stock has risen 51.4% in the past six months. A key driver of the increase is Merck’s improved outlook for ...

The F.D.A. approved Merck’s injected version of its blockbuster infusion Keytruda. The company says it will be quicker and easier, but it stands to slow the adoption of cheaper competitors and ...

This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. Oncology drug development is no longer a singles market as ...

(Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial ...

The FDA has approved Keytruda Qlex, an injected version of a popular cancer drug that until now has only been available via infusion. The FDA approved a new injected version of the cancer ...

FDA approves a PD-L1 test to help identify patients with esophageal or gastroesophageal junction (GEJ) cancer who may benefit ...

The combination of Padcev and Keytruda has once again delivered strong results, this time significantly improving overall survival (OS) for patients with cisplatin-eligible muscle-invasive bladder ...